Advertisement
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1. Kotlarz H, Gunnarsson CL, Fang H, et al. Insurer and out-of-pocket costs of osteoarthritis in the US: evidence from national survey data. Arthritis Rheum 2009; 60: 3546–3553.
-
2. Wilke VL, Robinson DA, Evans RB, et al. Estimate of the annual economic impact of treatment of cranial cruciate ligament injury in dogs in the United States. J Am Vet Med Assoc 2005; 227: 1604–1607.
-
3. Wang Q, Rozelle AL, Lepus CM, et al. Identification of a central role for complement in osteoarthritis. Nat Med 2011; 17: 1674–1679.
-
4. Garner BC, Stoker AM, Kuroki K, et al. Using animal models in osteoarthritis biomarker research. J Knee Surg 2011; 24: 251–264.
-
5. Rørvik AM, Grøndahl AM. Markers of osteoarthritis: a review of the literature. Vet Surg 1995; 24: 255–262.
-
6. Morozzi G, Fabbroni M, Bellisai F, et al. Cartilage oligomeric matrix protein level in rheumatic diseases: potential use as a marker for measuring articular cartilage damage and/or the therapeutic efficacy of treatments. Ann N Y Acad Sci 2007; 1108: 398–407.
-
7. Lohmander LS. What is the current status of biochemical markers in the diagnosis, prognosis and monitoring of osteoarthritis? Baillieres Clin Rheumatol 1997; 11: 711–726.
-
8. Kuroki K, Stoker AM, Sims HJ, et al. Expression of Toll-like receptors 2 and 4 in stifle joint synovial tissues of dogs with or without osteoarthritis. Am J Vet Res 2010; 71: 750–754.
-
9. Goldring MB. The role of cytokines as inflammatory mediators in osteoarthritis: lessons from animal models. Connect Tissue Res 1999; 40: 1–11.
-
10. Kuroki K, Cook CR, Cook JL. Subchondral bone changes in three different canine models of osteoarthritis. Osteoarthritis Cartilage 2011; 19: 1142–1149.
-
11. Havlis J, Thomas H, Sebela M, et al. Fast-response proteomics by accelerated in-gel digestion of proteins. Anal Chem 2003; 75: 1300–1306.
-
12. Eng JK, McCormack AL, Yates JR III. An approach to correlate tandem mass spectral data of peptides with aminoacid sequences in a protein database. J Am Soc Mass Spectrom 1994; 5: 976–989.
-
13. Gobezie R, Kho A, Krastins B, et al. High abundance synovial fluid proteome: distinct profiles in health and osteoarthritis. Arthritis Res Ther 2007; 9: R36.
-
14. Guo D, Tan W, Wang F, et al. Proteomic analysis of human articular cartilage: identification of differentially expressed proteins in knee osteoarthritis. Joint Bone Spine 2008; 75: 439–444.
-
15. de Seny D, Sharif M, Fillet M, et al. Discovery and biochemical characterisation of four novel biomarkers for osteoarthritis. Ann Rheum Dis 2011; 70: 1144–1152.
-
16. Wu J, Liu W, Bemis A, et al. Comparative proteomic characterization of articular cartilage tissue from normal donors and patients with osteoarthritis. Arthritis Rheum 2007; 56: 3675–3684.
-
17. Morgan BP. The complement system: an overview. Methods Mol Biol 2000; 150: 1–13.
-
18. Choi NH, Mazda T, Tomita M. A serum protein SP40,40 modulates the formation of membrane attack complex of complement on erythrocytes. Mol Immunol 1989; 26: 835–840.
-
19. Carter SD, Bell SC, Bari AS, et al. Immune complexes and rheumatoid factors in canine arthritides. Ann Rheum Dis 1989; 48: 986–991.
-
20. Bradley K, North J, Saunders D, et al. Synthesis of classical pathway complement components by chondrocytes. Immunology 1996; 88: 648–656.
-
21. Cromwell WC, Barringer TA. Low-density lipoprotein and apolipoprotein B: clinical use in patients with coronary heart disease. Curr Cardiol Rep 2009; 11: 468–475.
-
22. Olofsson SO, Borèn J. Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis. J Intern Med 2005; 258: 395–410.
-
23. Boren J, Lee I, Zhu W, et al. Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100. J Clin Invest 1998; 101: 1084–1093.
-
24. Tsimikas S, Miller YI. Oxidative modification of lipoproteins: mechanisms, role in inflammation and potential clinical applications in cardiovascular disease. Curr Pharm Des 2011; 17: 27–37.
-
25. Miller YI, Viriyakosol S, Worrall DS, et al. Toll-like receptor 4-dependent and -independent cytokine secretion induced by minimally oxidized low-density lipoprotein in macrophages. Arterioscler Thromb Vasc Biol 2005; 25: 1213–1219.
-
26. Bae YS, Lee JH, Choi SH, et al. Macrophages generate reactive oxygen species in response to minimally oxidized low-density lipoprotein: toll-like receptor 4- and spleen tyrosine kinase-dependent activation of NADPH oxidase 2. Circ Res 2009; 104: 210–221.
-
27. Choi SH, Harkewicz R, Lee JH, et al. Lipoprotein accumulation in macrophages via toll-like receptor-4-dependent fluid phase uptake. Circ Res 2009; 104: 1355–1363.
-
28. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 473–480.
-
29. Soran N, Altindag O, Cakir H, et al. Assessment of paraoxonase activities in patients with knee osteoarthritis. Redox Rep 2008; 13: 194–198.
-
30. Ganfornina MD, Do Carmo S, Lora JM, et al. Apolipoprotein D is involved in the mechanisms regulating protection from oxidative stress. Aging Cell 2008; 7: 506–515.
-
31. Russell ST, Zimmerman TP, Domin BA, et al. Induction of lipolysis in vitro and loss of body fat in vivo by zinc-alpha2-glycoprotein. Biochim Biophys Acta 2004; 1636: 59–68.
-
32. Jmeian Y, El Rassi Z. Micro-high-performance liquid chromatography platform for the depletion of high-abundance proteins and subsequent on-line concentration/capturing of medium and low-abundance proteins from serum. Application to profiling of protein expression in healthy and osteoarthritis sera by 2-D gel electrophoresis. Electrophoresis 2008; 29: 2801–2811.
-
33. Benditt EP, Meek RL. Expression of the third member of the serum amyloid A gene family in mouse adipocytes. J Exp Med 1989; 169: 1841–1846.
-
34. O'Hara R, Murphy EP, Whitehead AS, et al. Acute-phase serum amyloid A production by rheumatoid arthritis synovial tissue. Arthritis Res 2000; 2: 142–144.
-
35. Zerega B, Pagano A, Pianezzi A, et al. Expression of serum amyloid A in chondrocytes and myoblasts differentiation and inflammation: possible role in cholesterol homeostasis. Matrix Biol 2004; 23: 35–46.
-
36. Coetzee GA, Strachan AF, van der Westhuyzen DR, et al. Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. J Biol Chem 1986; 261: 9644–9651.
-
37. Tam SP, Flexman A, Hulme J, et al. Promoting export of macrophage cholesterol: the physiological role of a major acute-phase protein, serum amyloid A 2.1. J Lipid Res 2002; 43: 1410–1420.
-
38. Tsezou A, Iliopoulos D, Malizos KN, et al. Impaired expression of genes regulating cholesterol efflux in human osteoarthritic chondrocytes. J Orthop Res 2010; 28: 1033–1039.
-
39. Ritchie RF, Palomaki GE, Neveux LM, et al. Reference distributions for the negative acute-phase serum proteins, albumin, transferrin and transthyretin: a practical, simple and clinically relevant approach in a large cohort. J Clin Lab Anal 1999; 13: 273–279.
-
40. Koch A, Weiskirchen R, Sanson E, et al. Circulating retinol binding protein 4 in critically ill patients before specific treatment: prognostic impact and correlation with organ function, metabolism and inflammation. Crit Care 2010; 14: R179.
-
41. Li TW, Zheng BR, Huang ZX, et al. Screening disease-associated proteins from sera of patients with rheumatoid arthritis: a comparative proteomic study. Chin Med J (Engl) 2010; 123: 537–543.
-
42. Hoj Nielsen A, Knudsen F. Angiotensinogen is an acute-phase protein in man. Scand J Clin Lab Invest 1987; 47: 175–178.
-
43. Housley J. Alpha-2-macroglobulin levels in disease in man. J Clin Pathol 1968; 21: 27–31.
-
44. Tortorella MD, Arner EC, Hills R, et al. Alpha2-macroglobulin is a novel substrate for ADAMTS-4 and ADAMTS-5 and represents an endogenous inhibitor of these enzymes. J Biol Chem 2004; 279: 17554–17561.
-
45. Luan Y, Kong L, Howell DR, et al. Inhibition of ADAMTS-7 and ADAMTS-12 degradation of cartilage oligomeric matrix protein by alpha-2-macroglobulin. Osteoarthritis Cartilage 2008; 16: 1413–1420.
-
46. Harp JB, DiGirolamo M. Components of the renin-angiotensin system in adipose tissue: changes with maturation and adipose mass enlargement. J Gerontol A Biol Sci Med Sci 1995; 50: B270–B276.
-
47. Milner JM, Patel A, Rowan AD. Emerging roles of serine proteinases in tissue turnover in arthritis. Arthritis Rheum 2008; 58: 3644–3656.
-
48. Comerford EJ, Smith K, Hayashi K. Update on the aetiopathogenesis of canine cranial cruciate ligament disease. Vet Comp Orthop Traumatol 2011; 24: 91–98.
-
49. Cabrera SY, Owen TJ, Mueller MG, et al. Comparison of tibial plateau angles in dogs with unilateral versus bilateral cranial cruciate ligament rupture: 150 cases (2000–2006). J Am Vet Med Assoc 2008; 232: 889–892.
-
50. Haskard DO, Boyle JJ, Mason JC. The role of complement in atherosclerosis. Curr Opin Lipidol 2008; 19: 478–482.
Advertisement
Expression of proteins in serum, synovial fluid, synovial membrane, and articular cartilage samples obtained from dogs with stifle joint osteoarthritis secondary to cranial cruciate ligament disease and dogs without stifle joint arthritis
Abstract
Objective—To identify proteins with differential expression between healthy dogs and dogs with stifle joint osteoarthritis secondary to cranial cruciate ligament (CCL) disease.
Sample—Serum and synovial fluid samples obtained from dogs with stifle joint osteoarthritis before (n = 10) and after (8) surgery and control dogs without osteoarthritis (9) and archived synovial membrane and articular cartilage samples obtained from dogs with stifle joint osteoarthritis (5) and dogs without arthritis (5).
Procedures—Serum and synovial fluid samples were analyzed via liquid chromatography–tandem mass spectrometry; results were compared against a nonredundant protein database. Expression of complement component 3 in archived tissue samples was determined via immunohistochemical methods.
Results—No proteins had significantly different expression between serum samples of control dogs versus those of dogs with stifle joint osteoarthritis. Eleven proteins (complement component 3 precursor, complement factor I precursor, apolipoprotein B-100 precursor, serum paraoxonase and arylesterase 1, zinc-alpha-2-glycoprotein precursor, serum amyloid A, transthyretin precursor, retinol-binding protein 4 precursor, alpha-2-macroglobulin precursor, angiotensinogen precursor, and fibronectin 1 isoform 1 preproprotein) had significantly different expression (> 2.0-fold) between synovial fluid samples obtained before surgery from dogs with stifle joint osteoarthritis versus those obtained from control dogs. Complement component 3 was strongly expressed in all (5/5) synovial membrane samples of dogs with stifle joint osteoarthritis and weakly expressed in 3 of 5 synovial membrane samples of dogs without stifle joint arthritis.
Conclusions and Clinical Relevance—Findings suggested that the complement system and proteins involved in lipid and cholesterol metabolism may have a role in stifle joint osteoarthritis, CCL disease, or both.
Contributor Notes
Dr. Garner's present address is Department of Pathology, College of Veterinary Medicine, University of Georgia, Athens, GA 30602.
Funded by the University of Missouri Research Board Grant.
The authors thank Dr. Brian Mooney for assistance with proteomic analysis.
Powered by PubFactory